Core Viewpoint - A product claiming to be "99% pure Antarctic krill oil" from "Beijing Tongrentang" actually contains no krill oil, misleading consumers and raising concerns about brand integrity and consumer protection [1][4]. Group 1: Product Misrepresentation - The product's packaging prominently features "Beijing Tongrentang," leading consumers to believe it is from a reputable source, while the actual brand is "Tongrentang (TRT)" [1]. - The product claims to have a phospholipid content of 43%, but it contains no krill oil at all, undermining the quality associated with the Tongrentang brand [1][4]. - The infringing company, Beijing Tongrentang (Sichuan) Health Industry Co., Ltd., is being sued by Beijing Tongrentang Health Pharmaceutical Co., Ltd. for trademark infringement [1][5]. Group 2: Manufacturer's Accountability - The manufacturer, Anhui Habao Pharmaceutical Co., Ltd., has faced multiple administrative penalties in the past three years for label non-compliance and advertising violations [3]. - The out-of-line pricing of the product raises questions about the manufacturer's practices, suggesting a lack of transparency and accountability [3][4]. - The infringing company claims ignorance of the misleading packaging, but the circumstances suggest otherwise, indicating potential complicity [3]. Group 3: Brand Integrity and Consumer Trust - The "Tongrentang universe" is described as a chaotic marketplace where many products misuse the Tongrentang name, threatening the brand's reputation built over centuries [4]. - Beijing Tongrentang emphasizes the importance of maintaining its brand integrity and has repeatedly stated that it has never authorized the use of its trademark by subsidiary companies [4]. - The company is committed to legal action to protect its brand and consumer rights, highlighting the need for stricter regulatory oversight to prevent such abuses [5][7].

百年老字号同仁堂，近日因一款"南极磷虾油"产品被推上舆论风口。上海市消保委检测发现，该产品标 识磷脂含量43%，实际检测结果为0，涉嫌虚假宣传。然而，同仁堂集团却回应称"没有这款产品"。一 场"造假"罗生门的背后，折射出这家药界老字号在品牌管控、业绩压力与治理结构上的多重风险。 一、产品造假还是品牌失控？"贴牌乱象"侵蚀信任根基 此次涉事产品标注为"北京同仁堂99%高纯南极磷虾油"，经销商为北京同仁堂（四川）健康药业有限公 司——一家由同仁堂集团间接持股的"孙公司"。尽管集团迅速撇清关系，称产品非其出品，但消费者在 电商平台以"北京同仁堂"为关键词搜索，仍可见大量贴牌商品，从保健食品到日用品，覆盖众多品类。 这类贴牌模式虽在短期内带来授权收入，却隐藏着巨大风险：一旦产品质量出现问题，消费者往往将矛 头直指"同仁堂"品牌本身。集团虽屡发声明禁止下属公司滥用商标，但实操中监管显然乏力。品牌价值 在一次次"贴牌—出事—否认"的循环中被不断稀释，长远来看，这种透支信誉的做法恐将动摇其百年积 累的信任根基。 二、业绩连续下滑，短视行为背后的经营压力 同仁堂近年财务表现并不乐观。2025年三季报显示，公司营收与净利润双双 ...

Core Viewpoint - The Shanghai Consumer Protection Committee has revealed that "Beijing Tongrentang" krill oil is suspected of being counterfeit, with the manufacturer admitting that the product does not contain the claimed "Antarctic krill oil" [2][3]. Group 1: Company Accountability - Anhui Habao Pharmaceutical Co., Ltd. stated that the disputed product was custom-ordered by Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. at a price significantly below normal levels [2]. - The Shanghai Consumer Protection Committee found that the involved companies engaged in deceptive practices, violating consumer rights and market integrity principles [2]. - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. denied knowledge of the alleged counterfeiting and attempted to evade responsibility during discussions with the committee [2]. Group 2: Consumer Protection Actions - The Shanghai Consumer Protection Committee urged Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. to conduct a self-examination, apologize to consumers, and recall the problematic products [3]. - The committee has notified relevant regulatory authorities in Sichuan about the situation [3]. - Beijing Tongrentang has ordered the cessation of sales of the disputed product and initiated a full process review and traceability [3].

Core Viewpoint - The investigation into 15 popular Antarctic krill oil products revealed significant discrepancies in labeling and actual content, raising concerns about consumer safety and the implications of the "private label" model in the industry [1][2] Group 1: Product Testing and Findings - The Shanghai Consumer Protection Commission commissioned a study that found a product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" contained 0% phospholipid, despite claiming a 43% phospholipid content [1] - The product is manufactured by Anhui Habio Pharmaceutical Co., Ltd., and distributed by Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. [1] Group 2: Brand Responsibility and Consumer Concerns - The incident has sparked widespread concern among consumers regarding the risks associated with the "private label" model, where well-known brands may not be the actual producers of the products [2] - The legal responsibility for product safety lies with both the brand owner and the actual manufacturer, as per the Food Safety Law Implementation Regulations [2]

Core Viewpoint - The company Tong Ren Tang is embroiled in a scandal regarding the authenticity of its Antarctic krill oil product, which has been found to contain no phospholipids despite claims of high purity [1][2][3] Group 1: Product Quality Issues - A product labeled "Beijing Tong Ren Tang 99% High Purity Antarctic Krill Oil" was found to have a phospholipid content of 0%, raising suspicions of fraud [1][2] - The Shanghai Consumer Protection Committee is investigating the product and has summoned the involved companies for explanations [2] - The product was sold at prices ranging from 35 to 100 yuan on various e-commerce platforms, with misleading marketing claims [2] Group 2: Company Response - On December 15, the company ordered the cessation of sales of the implicated product and initiated a full traceability check [3] - The company stated that the product was sold without authorization and plans to take legal action against the responsible parties [3] Group 3: Historical Context of Quality Issues - The company has faced multiple product quality scandals over the years, including issues with honey, mercury levels in products, and contamination in foot bath products [4][5][6] - These recurring issues have led to a significant erosion of consumer trust in the brand [6][7] Group 4: Financial Performance - The company's revenue and net profit have been declining, with a reported revenue of 133.08 billion yuan and a net profit of 11.78 billion yuan in the first three quarters of 2025, representing declines of 3.70% and 12.78% respectively [8] - The company's stock price has dropped significantly, from a peak of 64.28 yuan per share to around 33 yuan, resulting in a market capitalization of approximately 450 billion yuan, which is less than half that of competitors like Yunnan Baiyao and Pian Zai Huang [8]

Group 1 - The last two giant pandas in Japan, "Xiaoxiao" and "Leilei," are scheduled to return to China in early 2026, prompting a significant public farewell event at Ueno Zoo in Tokyo [1][3] - From December 16, Ueno Zoo implemented visitor restrictions for the panda viewing area, allowing each group of visitors only one minute to observe the pandas [1][5] - Long queues were reported, with visitors typically waiting over 40 minutes on weekdays and more than an hour on weekends to see the pandas [1][7] Group 2 - The Australian government has enacted a law prohibiting social media access for individuals under 16, with penalties for non-compliance reaching up to 49.5 million AUD (approximately 230 million RMB) [11] - This legislation has garnered international attention, with countries like the UK, France, Denmark, and Norway expressing support, and others like Indonesia and Malaysia exploring similar regulations [11] Group 3 - The Shanghai Consumer Protection Commission has raised concerns regarding a product labeled as "99% high-purity Antarctic krill oil" from Beijing Tongrentang, which was found to contain no actual krill oil [19][20] - The commission has urged the involved companies to conduct self-inspections, apologize to consumers, and recall the defective products [20]

Group 1 - The incident involving a product claiming "99% high purity" Antarctic krill oil, which was found to have a phospholipid content of 0, has led to a trust crisis for Tong Ren Tang, a brand with a 355-year history [1] - The involved product was produced under a private label, highlighting a lack of quality control due to uncontrolled brand authorization, which has damaged consumer trust and the brand's long-standing reputation [1] - The core asset of a time-honored brand is not the trademark but the trust built over generations through quality, as emphasized by Tong Ren Tang's principle of meticulous production and quality assurance [1] Group 2 - Many time-honored brands view trademark authorization as a quick profit method, but short-term gains do not equate to long-term brand value [2] - The Ministry of Commerce reports that among 1,455 "Chinese time-honored brands," nearly 1,000 are involved in intangible cultural heritage projects, indicating that these brands carry both commercial value and cultural significance [2] - Tong Ren Tang Group should not merely issue statements to evade responsibility but must establish a comprehensive quality control system and clarify the responsibilities associated with trademark authorization [2]

Core Viewpoint - The long-established brand Tong Ren Tang (600085.SH) is embroiled in a scandal regarding the authenticity of its Antarctic krill oil product, which has been found to contain no phospholipids despite claims of a 43% content [1][2]. Group 1: Product Scandal - The Shanghai Consumer Protection Commission released test results showing that a product labeled "Beijing Tong Ren Tang 99% High Purity Antarctic Krill Oil" had a phospholipid content of 0, raising suspicions of fraud [1][2]. - The product was sold at prices ranging from 35 to 100 yuan on various e-commerce platforms, with misleading claims about its quality and content [2]. - Tong Ren Tang has ordered the involved company, Anhui Habao Pharmaceutical Co., to cease distribution of the product and has initiated legal action against them for unauthorized use of its brand [3]. Group 2: Historical Issues - Tong Ren Tang has faced multiple product quality issues over the years, including incidents involving excessive nitrite levels, illegal additives, and contamination [5][6]. - The company has been involved in various scandals, such as the "honey incident" in 2018 and the mercury contamination in its Ren Dan product in 2024 [4][5]. Group 3: Financial Performance - The company's revenue and net profit have been declining, with a reported revenue of 133.08 billion yuan and a net profit of 11.78 billion yuan in the first three quarters of 2025, representing year-on-year declines of 3.70% and 12.78%, respectively [8]. - In 2024, the company experienced a slowdown in growth, with revenue of 185.97 billion yuan, a mere 4.12% increase, and a net profit decline of 8.54% [7][8]. - The market performance has also been poor, with the stock price dropping from 64.28 yuan per share in May 2023 to around 33 yuan by December 2025, resulting in a market capitalization of approximately 450 billion yuan, significantly lower than competitors like Yunnan Baiyao and Pian Zai Huang [8].

Policy Developments - Jiangxi Province has introduced 13 measures to promote the high-quality development of the pharmaceutical retail chain industry, including support for enterprise integration, simplified approval processes, and encouragement of innovative business models [1] - The new policies aim to address industry pain points, such as supporting mergers and acquisitions, and promoting health service extensions like chronic disease management [1] Medical Device Approvals - The National Medical Products Administration has approved two innovative medical devices: a proton therapy system for treating malignant tumors and a deep brain stimulation system for opioid addiction treatment [2] Clinical Trials - Haikang announced that its subsidiary received clinical trial approval for four innovative drugs targeting inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy [3] Capital Market Developments - Changchun High-tech signed an exclusive licensing agreement for the GenSci098 injection project, potentially earning up to $1.365 billion in milestone payments [4][5] Industry Collaborations - Sunshine Nuohuo has partnered with Peking University to establish a joint laboratory focused on innovative drug development, particularly in cell and gene therapy [7] Regulatory Actions - The Shanghai Consumer Protection Committee has addressed issues related to Antarctic krill oil products from Beijing Tongrentang, highlighting quality control failures and potential misrepresentation [10][11]

Core Viewpoint - The Shanghai Consumer Protection Committee has raised concerns regarding the authenticity of Antarctic krill oil products marketed by Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd, leading to an investigation and potential legal actions against the involved parties [4][5][9]. Group 1: Product Issues - A product labeled as "99% high-purity Antarctic krill oil" was found to have a phospholipid content of 0%, despite claims of 43% on its packaging [4][5]. - The product's marketing included misleading statements such as "high content," "imported from Chile," and "highly purified," which were proven to be false [5]. Group 2: Company Accountability - Anhui Hab Pharmaceutical Co., Ltd, the manufacturer, admitted that the product did not contain the claimed Antarctic krill oil during production [4][5]. - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd, the distributor, denied knowledge of the alleged fraudulent activities and attempted to deflect responsibility [4][5]. Group 3: Regulatory Actions - The Shanghai Consumer Protection Committee has urged the distributor to conduct a self-examination, inform consumers of the situation, issue an apology, and recall the problematic products [5]. - The committee has also notified relevant regulatory authorities in Sichuan to monitor the situation [5]. Group 4: Company Background - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd was established in June 2000 and is a member of the Beijing Tongrentang Group, with a 51% stake held by Beijing Tongrentang Health Pharmaceutical Co., Ltd [7][8]. - The company has faced scrutiny in the past for similar issues, including false advertising related to fish oil products [10].